Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Exelixis has closed its public offering of seven million shares of common stock. Net proceeds of the offering are approximately $71.8 million, after deducting estimated offering expenses.
Subscribe to our email newsletter
The company also granted the underwriter a 30-day option to purchase up to an additional 1.05 million shares of common stock. Goldman, Sachs & Company acted as the sole underwriter for the offering.
The offering is being made pursuant to an effective automatic shelf registration statement.